CD59 and prostate cancer: In some instances, increased expression of CD59 correlates with overall decreased survival rates in patients with colorectal cancer (156), prostate cancer (157), and B cell lymphoma (158) while low CD59 expression in breast tumors correlates with increased invasiveness and poor survival (159).